PATH - Wayfind | Attorneys Supporting Communities RESEARCHANDDEVELOPMENTSPENDING Page$4$ $ PUBLICHEALTHSPENDING ... PATH's$Guiding$Principles$for$PrivateUSector$Collaboraon $

PATH  Dan  Laster    |  Chief  Opera1ng  Officer  and  General  Counsel  Developing  Products  to  Improve  Global  Health    

October  27  2016  

LAND  AREA  

Page  2  www.worldmapper.org  

POPULATION  

Page  3  www.worldmapper.org  

RESEARCH  AND  DEVELOPMENT  SPENDING  

Page  4  www.worldmapper.org  

PUBLIC  HEALTH  SPENDING  

Page  5  www.worldmapper.org  

VACCINE  PREVENTABLE  DEATHS  

Page  6  www.worldmapper.org  

SOLUT ION:    DR IVE  TRANSFORMATIVE   INNOVAT ION   IN    GLOBAL  HEALTH  

PATH/Umit  Kartoglu      

Work  in  more  than  70  countries    150  million  people  reached  each  year  (average)  

Our  global  impact  

6.3  million  people    reached  with  rice  for1fied  with  cri1cal  micronutrients  

6.2  million  lives  saved  with  PATH-­‐pioneered  approaches  to  malaria  control  

6  billion  vaccine  vial    monitors  ensuring  that  vaccines  are  potent  when  given  

AcceleraHng  global  health  innovaHons  

ExperHse  and  programs  across  five  plaNorms  

Working  across  the  value  chain,  focusing  on  the  middle  

Research  /    Design  

Develop  /    Validate  

Approve  /    Recommend  

Introduce  /    Op1mize  

Scale  up  /    Apply  

Vaccines   Drugs   Diagnos1cs   Devices   System  &  Service  Innova1ons  

PATH’S  ROLE :     CATALYZ ING  CROSS -­‐SECTOR  COLLABORAT ION  FOR   IMPACT…      

…   b y   b u i l d i n g   e v i d e n c e   a n d   b r i d g i n g   t h e   v a l u e   c h a i n   o f   i n n o v a H o n  

C i v i l   S o c i e t y  

P u b l i c   P r i v a t e  

IMPACT  

Scale-­‐up  Develop/  Validate    IntroducHon  Research/  

Design  Regulatory/  

Policy  

10      

PotenHal  returns  

Developm

ent  risk  

Private  sector  

Developing  world  risk/return  

PARTNERING  UPSTREAM:  PRODUCT  DEVELOPMENT  PARTNERSHIPS   (PDP)  

Develop/  Validate   IntroducHon  Research/  

Design  Regulatory/  

Policy   Scale  up  

11      

•   Mi1gate  risk  •   Share  costs  

PotenHal  returns  

Developm

ent  risk  

Private  sector  

Developing  world  risk/return  

PARTNERING  UPSTREAM:    PRODUCT  DEVELOPMENT  PARTNERSHIPS  

PDP  

Develop/  Validate   IntroducHon  Research/  

Design  Regulatory/  

Policy   Scale  up  

12      

MUTUALLY  BENEF IC IAL ,  COLLABORATIVE  PRODUCT  DEVELOPMENT  PARTNERSHIPS    

                           WHAT  PATH  BRINGS  •  Exper1se  in  developing                      country  health  systems  

•  Presence  in  low-­‐income  countries  

•  Ability  to  strengthen    clinical  trial  capacity  

•  Financial  support  •  Technical  exper1se  •  Strategic  rela1onships  •  Intellectual  property  

WHAT  PARTNERS  BRING  •  Exper1se  in  product  development  

•  Scien1fic  and  technical  capacity  

•  Intellectual  property      •  Manufacturing  facili1es  &  equipment  

•  Large-­‐scale  distribu1on  systems  

•  Market-­‐based    approach  

Mutual  ben

efit  

Develop/  Validate   IntroducHon  Research/  

Design  Regulatory/  

Policy   Scale  up  

13      

DRIVERS  OF  PDP  PARTNERSHIP  DIVERSITY  

State  of  Science  or  Technology  

Intellectual  Property  

Time  to  Market  

Clarity  of  Market  

Distribu1on  System  Readiness  

Partnership  Complexity  

Less  certain  More  certain  

Develop/  Validate   IntroducHon  Research/  

Design  Regulatory/  

Policy   Scale  up  

14      

CRITICAL  TERMS  FOR  GLOBAL  ACCESS  

Supply  

Develop/  Validate   IntroducHon  Research/  

Design  Regulatory/  

Policy   Scale  up  

15      

CASE:  MENINGITIS  A  VACCINE  

State  of  Science  or  Technology  

Intellectual  Property  

Time  to  Market  

Clarity  of  Market  

Distribu1on  System  Readiness  

Partnership  Complexity  

Less  certain  More  certain  

Develop/  Validate   IntroducHon  Research/  

Design  Regulatory/  

Policy   Scale  up  

16      

Partnering  to  eliminate  meningi1s  epidemics  

220  million  protected:  zero  cases  of  meningi1s  A  

Legend  By  2020,  the  vaccine  will  prevent:  

•  1  million  cases  •  150,000  deaths  

•  250,000  cases  of  severe  disability  

MULTI-­‐SECTOR  PARTNERSHIPS  ARE  EVOLVING…  

19      

MULTI-­‐SECTOR  PARTNERSHIPS  ARE  EVOLVING…  

QUESTIONS?  

PATH/  Gabe  Bienczycki  

L INKS  TO  PATH  RESOURCES  

Public-­‐Private  Partnerships  for  Global  Health:  How  PATH  Advances  Technologies  Through  Cross-­‐Sector  Collabora1on  PATH's  Guiding  Principles  for  Private-­‐Sector  Collabora1on  PATH's  Framework  for  Product  Introduc1on  PATH’s  Commercializa1on  Toolkit  for  Small-­‐  and  Medium-­‐Sized  Enterprises:  Execu1ve  Summary  Developing  a  Total  Market  Plan  for  Family  Planning  in  Vietnam:  An  Innova1ve  Public  and  Private  Collabora1on  to  Enhance  Equity  and  Sustainability  

21